Previous 10 | Next 10 |
Mercurity Fintech Holding (MFH) +65%. Fast Radius (FSRD) +21%. Nikola (NKLA) +18% after investor event. Femasys (FEMY) +13%. BiondVax Pharmaceuticals (BVXV) +13% on research pact to develop nanosized antibody therapies. Incannex Healthcare (IXHL) +12%. D-MARKET Elektronik&...
HOOKIPA Pharma press release (NASDAQ:HOOK): Q4 GAAP EPS of -$0.65 misses by $0.03. Revenue of $3.9M (-24.4% Y/Y) beats by $0.11M. The company expects to file an Investigational New Drug (IND) application for HB-300 in the third quarter of 2022. CEO comment: “With the recent capital rai...
Lead oncology candidate HB-200 demonstrated high antigen-specific T cell responses and encouraging anti-tumor activity in heavily pre-treated head and neck cancer patients HOOKIPA received FDA Fast Track designation and advanced HB-200 to Phase 2 trial in combination with pem...
OTCQX:CCHWF, CIH, OTCQX:CWBHF, DRI, FDS, HOOK, OTCQX:JUSHF, KC, MOMO, NEOG, SNX, TFFP, TITN, TMDI For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open
Hoopika Pharma (NASDAQ:HOOK) has promoted Klaus Orlinger, Ph.D. to Chief Scientific Officer, most recently serving as Executive Vice President, Research. Since joining HOOKIPA in February 2012, Klaus has played a leading role in driving HOOKIPA’s arenaviral platform to the clinic ...
NEW YORK and VIENNA, Austria, March 22, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that Klaus Orlinger, Ph.D. has been promoted to ...
NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full yea...
Four poster presentations expand evidence on potent T cell responses, ability to break tolerance and potential combination use beyond PD-1 inhibitors Preclinical data suggest synergy of arenaviral immunotherapy with 4-1BB agonists or cell therapy, resulting in better tumor control...
Gainers: Organogenesis (NASDAQ:ORGO) +24%. CytomX Therapeutics (NASDAQ:CTMX) +13%. X4 Pharmaceuticals (NASDAQ:XFOR) +13%. MannKind (NASDAQ:MNKD) +10%. Allied Healthcare (NASDAQ:AHPI) +6%. Losers: Karyopharm Therapeutics (NASDAQ:KPTI) -31%. Bright Health Grou...
Karyopharm Therapeutics (NASDAQ:KPTI) -29% after US Regulatory update on Selinexor in advanced or recurrent endometrial cancer. GoHealth (NASDAQ:GOCO) -24% on expecting Q4 revenue below estimates. Bright Health (NYSE:BHG) -10% on Q4 earnings release. Telefonaktie...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...
2024-07-09 09:02:05 ET Hookipa Pharma Inc (HOOK) announced stock split at a ratio of 1-for-10 on 2024-07-10 ... Full story available on KlickAnalytics.com